Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma
First publishedAug 19, 10:49 UTC
Last updatedAug 19, 14:58 UTC · 11m ago
1 outlet
CNBC Top News2 outlets
Investing.com · Stock Market1 outlet
NBC News1 outlet
The Hill
5 outlets over time — hover a bar for its window & outletslast updated
Answer
Moderna and Merck's cancer vaccine showed promise in preventing melanoma recurrence in a large trial.
Reported by 5 outlets — NBC News, The Hill, CNBC Top News, Investing.com · Stock Market. See all sources ↓
A researcher works in the lab at the Moderna headquarters in Cambridge, Mass.
Read the full report at NBC News ↗
Why it matters
Moderna and Merck worked together on a cancer vaccine. They tested it in a large trial. The vaccine showed promise in preventing melanoma from coming back.
In brief
- What's the story?
- Moderna and Merck's cancer vaccine showed promise in preventing melanoma recurrence in a large trial.
- How widely is it covered?
- 5 outlets, average source rating 6.8/10.
- When was it last updated?
- 11m ago.
Different angles across outlets
Coverage map
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card4 outlets1CoverageScouting report
Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
Sources4TypeCoverage
Sources (5)
Avg source rating 6.8/10Processing cluster
A1A2A3B1B2B3